Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis - PubMed (original) (raw)
. 2009 Jan-Feb;2(1):73-80.
doi: 10.3892/mmr_00000064.
Akihiko Gemma, Akinobu Yoshimura, Yoko Hosoya, Michiya Nara, Yukio Hosomi, Tetsuya Okano, Shinobu Kunugi, Kiyoshi Koizumi, Yuh Fukuda, Kazutsugu Uematsu, Kazuo Shimizu, Shoji Kudoh
Affiliations
- PMID: 21475793
- DOI: 10.3892/mmr_00000064
Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis
Kiyoshi Takenaka et al. Mol Med Rep. 2009 Jan-Feb.
Abstract
Patients with idiopathic pulmonary fibrosis (IPF) have an increased risk of developing lung cancer. To identify key molecules involved in malignant transformation in IPF, we analyzed the expression profiles of lung and lung tumor tissue from patients with lung cancer and IPF (lung cancer/IPF) using cDNA arrays and real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Reduced expression of the Smad4 gene was identified in all eight tumor samples from the lung cancer/IPF patients using real-time RT-PCR. Expression levels of Smad4 were significantly lower in tumors from lung cancer/IPF patients than in those from lung cancer patients without IPF or in lung cancer cell lines (p<0.01). Mutational analysis of TGF-β type II receptor and Smad4 was performed using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP). The methylation status of the Smad4 promoter was analyzed using methylation-specific PCR with subsequent sequence analysis. No mutations were detected in the eight tumor samples, but hypermethylated regions were detected in the Smad4 promoter in two of the eight tumors with reduced Smad4 expression. Promoter reporter assays showed that the activity of the Smad4 promoter containing the sequence of the methylated region was significantly stronger than that of the Smad4 promoter with a deleted methylated region (p<0.002). Our findings indicate that the loss of the growth inhibitory response to TGF-β signaling may be crucial in pulmonary carcinogensis or in the progression of lung cancer in IPF patients in whom TGF-β is overexpressed; hypermethylation of the Smad4 promoter region may be one mechanism by which this occurs. These findings are useful for the development of preventive measures or treatment for lung cancer patients with IPF.
Similar articles
- Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis.
Samara KD, Antoniou KM, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, Siafakas NM. Samara KD, et al. Int J Oncol. 2012 May;40(5):1397-404. doi: 10.3892/ijo.2012.1374. Epub 2012 Feb 15. Int J Oncol. 2012. PMID: 22344343 - Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, Wake N, Mogi A, Shitara Y, Takenoshita S. Wang D, et al. Cancer Res. 2000 Aug 15;60(16):4507-12. Cancer Res. 2000. PMID: 10969799 - Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G, Hu X, Lu C, Su C, Luo S, Luo ZW. Wang G, et al. Lung Cancer. 2008 Nov;62(2):162-72. doi: 10.1016/j.lungcan.2008.03.023. Epub 2008 May 12. Lung Cancer. 2008. PMID: 18468719 - Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T, Munakata M, Ohtsuka Y, Nisihara H, Nasuhara Y, Kamachi-Satoh A, Dosaka-Akita H, Homma Y, Kawakami Y. Takahashi T, et al. Cancer. 2002 Aug 1;95(3):624-33. doi: 10.1002/cncr.10708. Cancer. 2002. PMID: 12209756 - Reduced transcription of the RB2/p130 gene in human lung cancer.
Xue Jun H, Gemma A, Hosoya Y, Matsuda K, Nara M, Hosomi Y, Okano T, Kurimoto F, Seike M, Takenaka K, Yoshimura A, Toyota M, Kudoh S. Xue Jun H, et al. Mol Carcinog. 2003 Nov;38(3):124-9. doi: 10.1002/mc.10152. Mol Carcinog. 2003. PMID: 14587097
Cited by
- DNA methylation modification in Idiopathic pulmonary fibrosis.
Ren L, Chang YF, Jiang SH, Li XH, Cheng HP. Ren L, et al. Front Cell Dev Biol. 2024 Jun 10;12:1416325. doi: 10.3389/fcell.2024.1416325. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38915445 Free PMC article. Review. - Innovative Pre-Clinical Data Using Peptides to Intervene in the Evolution of Pulmonary Fibrosis.
Simon KS, Coelho LC, Veloso PHH Jr, Melo-Silva CA, Morais JAV, Longo JPF, Figueiredo F, Viana L, Silva Pereira I, Amado VM, Mortari MR, Bocca AL. Simon KS, et al. Int J Mol Sci. 2023 Jul 4;24(13):11049. doi: 10.3390/ijms241311049. Int J Mol Sci. 2023. PMID: 37446227 Free PMC article. - CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
Fukuizumi A, Noro R, Seike M, Miyanaga A, Minegishi Y, Omori M, Hirao M, Matsuda K, Kunugi S, Nishiwaki K, Morimoto M, Motohashi H, Ohwada H, Usuda J, Gemma A. Fukuizumi A, et al. JTO Clin Res Rep. 2021 Sep 24;2(11):100232. doi: 10.1016/j.jtocrr.2021.100232. eCollection 2021 Nov. JTO Clin Res Rep. 2021. PMID: 34746885 Free PMC article. - Extracellular matrix proteins produced by stromal cells in idiopathic pulmonary fibrosis and lung adenocarcinoma.
Kreus M, Lehtonen S, Skarp S, Kaarteenaho R. Kreus M, et al. PLoS One. 2021 Apr 27;16(4):e0250109. doi: 10.1371/journal.pone.0250109. eCollection 2021. PLoS One. 2021. PMID: 33905434 Free PMC article. - Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?
Lettieri S, Oggionni T, Lancia A, Bortolotto C, Stella GM. Lettieri S, et al. Int J Mol Sci. 2021 Mar 12;22(6):2882. doi: 10.3390/ijms22062882. Int J Mol Sci. 2021. PMID: 33809111 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Miscellaneous